XML 25 R43.htm IDEA: XBRL DOCUMENT v2.3.0.15
Acquisitions (Details) (USD $)
In Millions, unless otherwise specified
9 Months Ended
Sep. 06, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH [Member]
Sep. 30, 2010
Biogen Idec Hemophilia [Member]
Sep. 30, 2011
Biogen Dompe SRL [Member]
Dec. 17, 2011
Biogen Idec International Neuroscience GmbH [Member]
Sep. 30, 2011
Biogen Idec International Neuroscience GmbH [Member]
Acquisitions (Textuals) [Abstract]     
Cash portion of consideration$ 152.9  $ 32.5 
Value of contingent consideration42.5  395.0 
Fair value of contingent consideration38.8  81.287.1
Receivables purchased as part of acquisition  104.6  
Loss recognized upon disposition  1.8  
Stock acquired in acquisition   100.00% 
Payment to former shareholders of Syntonix Pharmaceuticals $ 40.0